Gastrointestinal Conditions News

Participation in the Pediatric Academic Societies Meeting is back to pre-COVID-19 levels of engagement, according to one of the event’s program chairs.

The White House has accepted a $25,000 commitment from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, which will help advance the administration’s goal to end hunger and nutrition disparities by 2030.

The FDA has approved Mirum Pharmaceuticals’ Livmarli oral solution for treatment of cholestatic pruritus in patients aged 5 years and older with progressive familial intrahepatic cholestasis, according to a company release.

Postoperative antibiotic use did not improve rates of surgical site infection among pediatric patients with nonperforated appendicitis and gangrenous, suppurative or exudative findings, according to data in JAMA Surgery.

Treatment with Stelara for inflammatory bowel disease did not increase the risk for adverse maternal or fetal pregnancy outcomes, and infants exposed in utero reached developmental milestones in the first year of life, data showed.

Diagnostic stewardship, along with targeted prevention efforts and a testing and treatment clinical care pathway, reduced hospital-onset cases of Clostridioides difficile by more than 50% in a children’s hospital, researchers reported.

Treatment with once-daily linaclotide was well-tolerated and resulted in significant improvement in spontaneous bowel movements and stool consistency vs. placebo among children with functional constipation, researchers reported.

LAS VEGAS — Supplementation with prebiotic oligofructose-enriched inulin resulted in short-term microbiome changes as early as 4 weeks among children with inflammatory bowel disease, according to a presenter at Crohn’s & Colitis Congress.

LAS VEGAS — Although a substantial proportion of children with Crohn’s disease had growth disturbances at initiation of anti-tumor necrosis factor therapy, “significant improvement” was noted up to 24 months after treatment, data showed.

A single dose of a typhoid conjugate vaccine provided protection for at least 4 years among children aged 9 months to 12 years enrolled in a phase 3 trial in Malawi, according to results published in The Lancet.